Weisman A, et al. - In an allopurinol-treated diabetes cohort, researchers evaluated the correlation between allopurinol and mortality and cardiovascular results. The study sample consisted of eligible subjects between April 1, 2002, and March 31, 2012, who were ≥ 66 years of age with diabetes and the first prescription for allopurinol and were followed until March 31, 2016. According to this population-based retrospective cohort study, allopurinol was related to decreased risk of a composite outcome of all-cause mortality, non-fatal cardiovascular events (myocardial infarction, revascularization procedure, or stroke) or congestive heart failure (CHF) in males and females. Lack of cumulative dose effect and a positive outcome of tracer in males, however, suggest residual bias.